ArticleGut2001
The significance of cagA(+) Helicobacter pylori in reflux oesophagitis.
Article in Gut, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review.BMJ (Clinical research ed.) · 2003Pooled it
- Does a relationship still exist between gastroesophageal reflux and Helicobacter pylori in patients with reflux symptoms?World journal of surgical oncology · 2014Trial
- Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project.BMJ (Clinical research ed.) · 2004Trial
- The relationship between helicobacter pylori infection and gastro-esophageal reflux disease.North American journal of medical sciences · 2011Article
- Risk of oesophageal cancer by histology among patients hospitalised for gastroduodenal ulcers.Gut · 2007Article
- Epidemiology of gastric cancer.World journal of gastroenterology · 2006Review
- 23 years of the discovery of Helicobacter pylori: is the debate over?Annals of clinical microbiology and antimicrobials · 2005Article
- Helicobacter pylori and gastroduodenal pathology: new threats of the old friend.Annals of clinical microbiology and antimicrobials · 2005Review
- Article
- Helicobacter pylori and Gastroesophageal Reflux Disease.Current treatment options in gastroenterology · 2004Article
- Article
- Role of corpus gastritis and cagA-positive Helicobacter pylori infection in reflux esophagitis.Journal of clinical microbiology · 2002Article
- Helicobacter pylori and gastrointestinal tract adenocarcinomas.Nature reviews. Cancer · 2002Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori is a gastroduodenal pathogen associated with ulceration, dyspepsia, and adenocarcinoma. Recent preliminary studies have suggested that H pylori may be protective for oesophageal adenocarcinoma. In addition, strains of H pylori identified by the presence of the cytotoxin associated gene A (cagA) are shown to have a significant inverse association with oesophageal adenocarcinoma. Given that cagA(+) H pylori may protect against oesophageal carcinoma, these strains may be protective for oesophagitis, a precursor of oesophageal carcinoma.
aimsThe aim of this study was to investigate the association between cagA(+) H pylori and endoscopically proved oesophagitis. PATIENTS: The study group included 1486 patients attending for routine upper gastrointestinal tract endoscopy.
methodsAt endoscopy the oesophagus was assessed for evidence of reflux disease and graded according to standard protocols. Culture and histology of gastric biopsy specimens determined H pylori status. The prevalence of cagA was identified by an antibody specific ELISA (Viva Diagnostika, Germany).
resultsH pylori was present in 663/1485 (45%) patients and in 120/312 (38%) patients with oesophagitis. Anti-CagA antibody was found in 499/640 (78%) H pylori positive patients. Similarly, anti-CagA antibody was found in 422/521 (81%) patients with a normal oesophagus and in 42/60 (70%) with mild, 24/35 (69%) with moderate, and 11/24 (46%) with severe oesophagitis. The risk of severe oesophagitis was significantly decreased for patients infected with cagA(+) H pylori after correction for confounding variables (odds ratio 0.57, 95% confidence interval 0.41-0.80; p=0.001).
conclusionsThese results suggest that infection by cagA(+) H pylori may be protective for oesophageal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.